FindTrial
Sign In

JNJ-67856633

DRUG4 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Chronic Lymphocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMetastatic Castration-resistant Prostate Cancer (mCRPC)Myelodysplastic SyndromesNeoplasmsSolid Tumor, Adult

Phase 1

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
CompletedNCT03900598
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Start: 2019-04-03End: 2025-05-22Updated: 2025-06-22
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
CompletedNCT04657224
Janssen Research & Development, LLCChronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
Start: 2021-02-25End: 2025-01-16Updated: 2025-08-21
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
CompletedNCT04876092
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Start: 2021-07-28End: 2025-02-13Updated: 2025-08-21
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitationNCT06788509
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4
Start: 2024-12-30End: 2028-01-21Target: 80Updated: 2025-10-10

Related Papers

P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
HemaSphere2023-08-011 citations
861 Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy
Regular and Young Investigator Award Abstracts2021-11-013 citations
Abstract IA49: MALT1 targeting for B-cell lymphomas
Blood Cancer Discovery2020-11-01